OWG
RXRX icon

Oxford Wealth Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Oxford Wealth Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-46,826
Closed -$309K – 60
2024
Q3 		$309K Sell
46,826
-655
-1% -$4.7K 0.25% 52
2024
Q2 		$356K Buy
47,481
+36,841
+346% +$321K 0.24% 49
2024
Q1 		$106K Buy
+10,640
New +$118K 0.1% 60

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Oxford Wealth Group's RXRX Position: Q4 2024 in Review

Oxford Wealth Group sold out of Recursion Pharmaceuticals (RXRX) in Q4 2024, closing a stake of 46,826 shares — an estimated $309K sold.

Oxford Wealth Group first reported a position in RXRX in Q1 2024 and held it in 3 quarters. The position peaked at $356K in Q2 2024. 316 funds tracked by Wall St. Rank hold RXRX as of Q4 2024.

  • Oxford Wealth Group reported no remaining Recursion Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Oxford Wealth Group sold 46,826 Recursion Pharmaceuticals shares in Q4 2024, an estimated $309K.
  • Oxford Wealth Group first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Oxford Wealth Group's Recursion Pharmaceuticals position peaked at $356K in Q2 2024.
  • 316 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2024.

Based on Oxford Wealth Group's 13F filing for Q4 2024, filed 14 Feb 2025.